Home | Blog | Weight Loss | Mounjaro and Crohn’s Disease

Is taking Mounjaro safe if you have Crohn’s?

Mounjaro isn’t contraindicated for Crohn’s, and research suggests that GLP-1 treatments like Mounjaro are generally well-tolerated in people with this condition. They may even have extra benefits beyond weight loss, including reducing inflammation and helping support gut health.

That said, because we don’t have enough data yet, it’s important to use GLP-1 therapies cautiously and only under your clinician’s supervision if you have Crohn’s.

Medically reviewed by

Craig Marsh, Independent Prescriber

Go to

Reviewed on Dec 11, 2025. by Mr Craig Marsh Independent Prescriber Registered with GPhC (No. 2070724) Next review due on Dec 11, 2028.

Last updated on Jan 02, 2026.

Was this article useful?

Mounjaro is a dual GLP-1 and GIP medication that helps promote weight loss and may help lower inflammation.
Crohn’s disease causes parts of your digestive tract to become inflamed, leading to discomfort and flare-ups.
Using Mounjaro with Crohn’s comes with some potential risks, like side effects that can mask Crohn’s symptoms and possible interactions with other medications.
On the plus side, GLP-1 weight loss can help better manage your symptoms, offset steroid-related weight gain, and reduce complications.

How does Mounjaro work?

Mounjaro, more precisely its active ingredient, tirzepatide, works by mimicking two gut hormones called GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-dependent Insulinotropic Polypeptide). This means that it works in the body in a few different ways:

It helps stimulate insulin release only when your blood glucose is high, which helps stabilise your blood sugar levels.
It slows down how quickly food moves through your digestive system, which helps blunt spikes in blood sugar after meals and makes you feel fuller for longer.
It acts on the brain by reducing hunger and cravings, helping you eat less.

Just a heads-up: while Mounjaro (tirzepatide) actually works as a dual GLP-1/GIP treatment, we’ll call it a GLP-1 medication from here on. That’s because most studies compare it to other GLP-1 medications you might have heard of, like Wegovy (semaglutide) or Nevolat (liraglutide).

What is Crohn’s disease?

In short, Crohn’s disease is a type of inflammatory bowel disease (IBD) that causes parts of your digestive tract (most commonly your small and large intestines) to become swollen and irritated. The disease can be painful and debilitating, and lead to serious complications.

It’s a lifelong autoimmune condition. While it’s not known exactly what causes it, to result from a combination of genetics, environmental factors, and the way your immune system reacts. Research suggests that your immune system is mistakenly attacking normally harmless bacteria. Over time, this leads to chronic inflammation, which causes the symptoms of Crohn’s disease.

Although these can vary depending on what part of the gut is affected, some common symptoms of Crohn’s disease include:

recurring diarrhoea;
stomach cramps or pain (often after eating);
fatigue;
unintended weight loss; and:
blood or mucus in the stool.

Your diet and changes in digestion can worsen Crohn’s symptoms. For example, certain foods, additives, or high‑fat / processed foods may trigger flares or worsen symptoms.

What are the risks of using Mounjaro if you have Crohn’s?

Exacerbating symptoms

One way in which Mounjaro works is by slowing down gut motility. While this helps you feel satiated for longer and can support weight loss, it can also create gastrointestinal stress, which could worsen or overlap with symptoms of Crohn’s disease like stomach discomfort, diarrhoea, nausea, or constipation.

Also, by slowing down digestion, Mounjaro can be risky if you’ve got bowel narrowings (strictures) from Crohn’s, which can block the passage of food. Tirzepatide itself hasn’t been studied much in relation to this, but some reports suggest that other GLP‑1 medications can lead to intestinal blockages, so it’s best to use Mounjaro with caution in patients with known strictures or obstructive symptoms.

Masking symptoms or side effects

As we’ve mentioned above, Mounjaro can overlap with symptoms of Crohn’s disease. This means that treatment for an activating flare could be delayed, which can cause unnecessary discomfort.

On the other hand, Mounjaro side effects like nausea, bloating, or changes in bowel habits could be mistaken for early signs of a Crohn’s flare. This could mean that the correct course of action —usually delaying increasing the dose or pausing Mounjaro treatment—may also be delayed.

But a 2025 study of IBD patients over 12 months found that the rates of gastrointestinal adverse events (like bowel obstruction, IBD‑related hospitalisation, need for surgery, or escalation of IBD medication) did not increase significantly after starting GLP‑1 therapy.

So, while there might be isolated cases where Mounjaro side effects mask Crohn’s symptoms, the existing data suggest that, for most people, GLP-1s don’t increase gastrointestinal adverse events in patients with IBD. Your doctor may want to monitor you closely, but in general, using Mounjaro shouldn’t significantly affect your Crohn’s symptoms.

Complicating pancreatitis treatment

Pancreatitis is a rare but serious side effect of Mounjaro. It’s characterised by symptoms like severe, persistent abdominal pain (radiating to the back), nausea, vomiting, fever, and a rapid heartbeat.

Pancreatitis is also more common in people with Crohn’s disease.

But early signs of pancreatitis can be mistaken for a Crohn’s flare, or vice versa, since the symptoms often look very similar. Both conditions can cause abdominal pain, nausea, vomiting, diarrhoea, and general digestive upset.

This overlap can delay diagnosis and treatment, so if you have any new or unusually severe abdominal symptoms, it’s important that you seek immediate medical care.

Potential for drug interactions

Treatments to prevent or treat Crohn’s flare-ups include:

Medications to treat inflammation in your gut, like steroids, sulfasalazine, or mesalazine
Immunosuppressants (medicines that “dial down” your immune system so it’s less reactive to harmless triggers like normal gut bacteria), such as azathioprine or mercaptopurine
Biologics that target your immune system, such as adalimumab or infliximab
Medicines to treat your symptoms, such as painkillers, laxatives, or anti-diarrhoea medication

Although tirzepatide doesn’t have major direct interactions with Crohn’s medications, there are some things to take into account:

Mounjaro can slow down gastric emptying and can cause GI side effects like nausea, vomiting, and diarrhoea, which can affect the absorption of oral medications like mesalazine, sulfasalazine, azathioprine, or prednisolone.
Tirzepatide side effects like nausea or bloating could be confused with early flare symptoms, which might hold up any needed dose adjustments.
After starting Mounjaro, your body might start processing certain IBD treatments (like thiopurines) differently, which is why it’s important to keep an eye on your bloodwork to prevent unwanted effects, like elevated liver enzymes.

Make sure to inform your clinician about all the medications you’re taking, so that they can assess and prevent (if possible) any potential side effects.

Lack of large-scale research

Mounjaro (tirzepatide) is still a relatively new treatment, and we don’t yet have any large studies that focus specifically on people with Crohn’s disease. Most of what we know so far comes from small studies, retrospective analyses, mixed IBD populations, or studies that involved other GLP-1s, so the evidence is still limited. Because of this, we still don’t know its long-term effects on people with Crohn’s, how it affects active Crohn’s disease, or how safe it is in complicated Crohn’s cases (like strictures).

So while Mounjaro seems generally safe in people with IBD, we still need larger, Crohn’s-specific trials before we can gauge its safety and effectiveness in people with this condition.

What are the benefits of Mounjaro on Crohn’s?

On the flip side, weight loss from GLP‑1 therapy has been linked to lower rates of surgery and hospitalisation in people with IBD. So if you use it under careful supervision, and with continuity between your prescriber and gastroenterologist, Mounjaro may help with some aspects of Crohn’s, including:

Mounjaro delays gastric emptying

One of the most common symptoms of Crohn’s disease is having to go to the toilet frequently. While no large, randomised trials have looked at Mounjaro specifically for stool frequency or diarrhoea in IBD patients, we do know that it slows stomach emptying and affects gut motility.

A small study of three people with IBD suggests that Mounjaro may help reduce bowel frequency, which means that one potential benefit could be fewer trips to the bathroom.

Weight reduction may help alleviate symptoms

Carrying extra weight can put a lot of strain on your digestive system, and in people with IBD, it’s been linked to more flare-ups, more complications, and a lower chance of staying in remission.

That’s why losing weight can help relieve some of the strain on your gut. It’s also been linked to lower overall inflammation, which may help your digestive system run more smoothly and ease your symptoms.

That said, the evidence for this is still limited, and how GLP-1 weight loss affects Crohn’s can depend on things like your diet and lifestyle. No matter your health, weight loss should be gradual and carefully monitored by your clinician to make sure you’re getting the right amounts of the nutrients you need and to avoid triggering flare-ups.

Potentially lowers inflammation

It’s still early, but some studies suggest that GLP-1 treatments may help lower inflammation. For example, they’ve been shown to reduce markers like CRP, which is often higher in people with Crohn’s, especially during flares. In a study of 120 IBD patients treated with a GLP‑1 agonist (either semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) for at least 30 days, average CRP dropped significantly over one year (from 12.92 to 6.38 mg/dL).

Lower CRP levels suggest reduced overall inflammation, which might translate into fewer or less severe flare-ups for some people. That said, in the study above, people’s symptoms didn’t improve much, and the gut lining showed little visible healing. So while the drop in inflammation markers is encouraging, there isn’t enough proof to say that GLP-1 treatment can actually change the course of the disease.

Lowers risk of complications in some patients

A large retrospective analysis of more than 33,000 people indicated that GLP‑1‑treated IBD patients had fewer uses of steroids, hospital stays, and A&E visits compared with those who weren’t on these medications. This suggests that GLP-1 treatments like Mounajro may have a potential protective effect against IBD-related complications.

Helps manage steroid-induced weight gain

Many people with Crohn’s take steroids during flares, but long-term steroid use can lead to weight gain, increased appetite, and metabolic changes.

On the upside, studies suggest that using a weight-loss therapy like Mounjaro could help offset some of the steroid-related weight gain and thus make it easier to keep your metabolism and overall health on track long term.

Supporting this, in a meta-analysis that included 1,236 people with IBD, GLP-1 treatments led to an average weight loss of 5.71 kg, with treatment durations ranging from 3 to 18 months. Many of these people were also on standard IBD therapies, including corticosteroids and biologics. However, the study didn’t break down how steroid use specifically affected the weight-loss outcomes.

What to think about before using Mounjaro with Crohn’s

Mounjaro may be safe and even beneficial for people who want to lose weight and are living with Crohn’s disease. But there are some important factors you need to consider for your safety:

It’s important to let your IBD specialist know before starting GLP‑1 treatment.
Make sure your GLP-1 prescriber knows about your Crohn’s diagnosis, any medications you’re taking, or past surgeries, so they can identify possible drug interactions or contraindications.
While using Mounjaro, keep an eye out for side effects, especially anything that could point to pancreatitis, like severe abdominal pain, nausea, or vomiting.
It’s also important to stick to your usual disease monitoring and blood tests, so any changes in your condition are caught early.

And finally, if you’re ordering treatment online, make sure to disclose all information relating to your Crohn’s management. And it’s also a good idea to keep your GP in the loop as well, so that they can stay informed about your progress and give you advice on any health issues or concerns that come up during treatment.

How we source info.

When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.

Tell us what you want to hear.

Have a subject you’d like us to cover in a future article? Let us know.

Give us the inbox treatment.

We're making healthcare more about you. Sign up to our newsletter for personalised health articles that make a difference.

Disclaimer: The information provided on this page is not a substitute for professional medical advice, diagnosis, or treatment. If you have any questions or concerns about your health, please talk to a doctor.